BOULDER, Colo.–(BUSINESS WIRE)–BioLoomics, the company pioneering directed evolution of target degrading antibodies using human cells, today announced it has raised $8.7 million in seed financing to advance its proprietary platform technology and antibody degrader programs. The round was led by Innovation Endeavors, with participation from Horizons Ventures, TechU Ventures, Boom Capital Ventures, Hummingbird Nomads Fund, Cooley GC&H, BoxOne Ventures and Viswa Colluru (Founder of Enveda).
Click here to view original post
News
ESSENT BIOLOGICS RELEASES AMNION FOUNDATION’S FIRST HUMAN PRE-ECLAMPTIC PRIMARY CYTOTROPHOBLASTS AND HOFBAUER CELLS
Providing Researchers with Breakthrough Materials to Investigate Pre-Eclampsia CENTENNIAL, Colo., Aug. 23, 2022 /PRNewswire/ — Essent Biologics™, a leading supplier of human-derived cell and scaffold materials, today announced availability for investigational researchers to obtain human… […]
News
UMF|PerfectCLEAN Announces Ana Ruth Morales-Garcia as First Annual Education Hygiene Specialist Excellence Award Recipient
Colorado College staff member earns first annual award for her outstanding contribution to the school’s Student Health Center NORTHBROOK, Ill., May 10, 2023 /PRNewswire/ — UMF|PerfectCLEAN today announced that Ana Ruth Morales-Garcia, custodian at Colorado […]
News
New Colorado agency to address mental health care worker pipeline
A newly launched Colorado agency will coordinate and address statewide behavioral health needs. Click here to view original post
